Angstrom Capital

Angstrom Bio is a private U.S. diagnostics company developing sequencing-based molecular testing technologies that combine nanopore sequencing, proprietary nucleotide chemistry, and machine learning. The company is best known for its AMPD platform, which was launched for high-accuracy, high-frequency, low-cost COVID-19 and respiratory pathogen testing. Its stated focus is to expand the reach of amplicon sequencing diagnostics for the study, diagnosis, and treatment of disease, with an early emphasis on infectious disease and variant identification. Angstrom Bio has raised venture financing from GreyBird Ventures and has operated from Austin, Texas. Based on public information, it appears to be a small, active private company centered on infectious disease diagnostics rather than therapeutics.